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Abstract: Background: Human mesenchymal stem cells (hMSCs) show potential for therapeutic cellular cardiomyo-
plasty. However, a range of delivery methods, including direct intramyocardial injection, have resulted in poor 
engraftment in vivo. We used the in vivo rat heart model to study hMSC engraftment and retention in a normal beating 
heart. Materials and Methods: HMSCs transfected with green fluorescent protein were injected into the left ventricle (LV) 
of immunocompetent rats. Hearts were cryopreserved 30 minutes (Group A), 24 hours (Group B), and 5 days (Group C) 
post hMSC delivery. HMSC retention was estimated using confocal fluorescence microscopy and immunohistochemistry. 
Measured values were compared to projected GFP-positive cellular volumes. Immunohistochemical analyses probed for 
the presence of human cells with human prolyl 4-hydroxylase beta (p4hβ) and an immune response with murine 
monocyte/macrophage antigen (CD68). Results: HMSC retention decreased significantly from 30 minutes to 5 days 
(p<0.05). In Group A the projected GFP positive cellular volume of 31% correlated with measured values and was 
significantly greater than the 1% predicted cellular volume in Group C. Moreover, human p4hβ was detected in Groups A 
and B, and not in Group C. Conversely, CD68 was detected in Groups B and C and not in Group A. Conclusions: In 
immunocompetent rats, engraftment and retention of hMSCs delivered intramyocardially significantly declines over a five 
day period. The influx of monocytes/macrophages suggests an unfavorable micro-environment for exogenous stem cell 
survival, confirmed by the absence of human cells detected five days post injection.  
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INTRODUCTION 
 Recently, cellular cardiomyoplasty for myocardial repair 
has received significant attention as numerous cells demons-
trating the potential for differentiation towards a cardiomyo-
cyte phenotype have been identified. Embryonic stem cells, 
induced-pluripotent stem cells, umbilical cord blood cells, 
resident cardiac stem cells, adipose derived stem cells and 
mesenchymal stem cells (MSCs) are currently under investi-
gation [1-5]. While various delivery methods have been 
used, research suggests that direct intramyocardial injection 
may result in higher cell retention with an increased benefit 
to cardiac function [6, 7].  
 Regardless of their therapeutic potential, the survival and 
engraftment of transplanted cells beyond a few hours is vital 
in their ability to provide a beneficial effect. However, 
studies have reported low levels of cell retention across a 
variety of delivery methods [8, 9]. These reports suggest that 
up to 90% of transplanted cells are either lost or die soon 
after delivery due to hypoxia, myocardial inflammation, or 
the physical stresses associated with the implantation proce-
dure [10]. Even with direct intramyocardial delivery, the 
majority of delivered cells may be lost due to mechanical 
washout, especially in a beating heart [11, 12]. Transplanted 
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cells that remain in the host tissue are further challenged by 
biological factors such as myocardial inflammation and 
potential immune reactions. 
 As early cell loss has become apparent, in vivo studies 
have attempted to quantify the retention of transplanted cells 
in the host myocardium. Most non-invasive imaging app-
roaches such as magnetic resonance imaging can identify 
very large numbers of cells [13]. For more sensitive app-
roaches, researchers have utilized labeled cells with quantum 
dots or cells transfected to express a fluorescent protein [14]. 
Herein, we apply an established method to estimate the 
retention of human MSCs transfected with a gene expressing 
a green fluorescent protein (GFP-hMSCs) injected into 
normal rat myocardium [15]. Cell retention estimates 
correlate with measured values, confirming that significant 
cell loss occurs within 5 days of cardiomyoplasty. Factors 
such as hypoxia, washout, and the physical stresses on the 
cells associated with direct injection are possible causes of 
cell loss along with the slower biological processes.  
MATERIAL AND METHODS 
hMSC Preparation 
 GFP-hMSCs were obtained from Tulane University at 
passage 3 (Tulane Center for Gene Therapy NIH, Grant # 
P40RR017447), cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 16.5% fetal bovine 
serum (Hyclone, Thermo Fisher Scientific, Waltham, MA), 
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penicillin (100 units/ml), streptomycin (100 µg/ml ) 
amphotericin B solution (0.25 µg/ml) and incubated at 37o C 
and 5% CO2. At 80% confluency GFP-hMSCs were harves-
ted using TrypLE Express, counted on a hemacytometer 
using the trypan blue method, washed twice with sterile 
phosphate-buffered saline (PBS, USB Corp., Cleveland, 
OH), and resuspended at a concentration of 5 x 105 cells per 
10µl of sterile PBS. GFP-hMSCs were maintained on wet ice 
with a cell viability of 96% or better observed prior to injec-
tion. (All media and supplements supplied by Invitrogen, 
Carlsbad, CA unless otherwise stated). 
Surgical Protocol 
 All surgical procedures were performed in accordance 
with accepted guidelines for the care and treatment of 
experimental animals of the National Institutes of Health 
[16]. Appropriate Institutional Animal Care and Use 
Committee approval from East Carolina University was 
obtained. Female Sprague Dawley rats (Charles River, 
Wilmington, MA) weighing 300-325gm were anesthetized 
with an intraperitoneal injection of ketamine (90 mg/ml) and 
xylazine (10 mg/ml) at 0.1 ml/100 gm weight, intubated, and 
ventilated (Harvard Apparatus, Holliston, MA). A left 
thoracotomy in the fourth intercostal space allowed for 
adequate exposure of the heart. GFP-hMSCs suspended in 
sterile PBS (5 x 105/10  µl) were injected into the anterior left 
ventricular (LV) wall of the beating heart using a 25 µl 
syringe with a 30G needle (Hamilton, Reno, Nevada). After 
injection of GFP-hMSCs the surgical site was closed, and 
animals were recovered. Animals were randomly assigned to 
one of three survival groups: Group A, 30 minutes (n=5); 
Group B, 24 hours (n =5); and Group C, 5 days (n =7). 
Control animals for each group were given an injection of 10 
ul sterile saline. 
Tissue Preparation 
 All animals were euthanized at the appropriate time 
points with CO2 exposure. Hearts were rapidly excised and 
rinsed in PBS. The LV was removed, embedded in optimal 
cutting temperature compound (Tissue-Tek Sakura, 
Torrance, CA), snap-frozen, and stored at -80o C. The LV 
was cut along a sagittal plane, parallel to the septum, in 10 
µm sections spanning the epicardial to endocardial surface, 
shown in Fig. (1). Every other tissue section was analyzed by 
fluorescence microscopy to detect the presence of GFP 
positive cells. Immunohistochemistry for human cells and 
rodent immune cells was performed on tissue sections where 
GFP positive cells and/or the injection site was identified. 
Immunohistochemistry 
 Left ventricular tissue sections were fixed in 4% 
paraformaldehyde in PBS, permeabilized with 0.1% Triton 
X-100 and blocked with 3% bovine serum albumin (BSA, 
Sigma-Aldrich, St. Louis, MO). The presence of hMSCs in 
the LV was demonstrated using a monoclonal antibody 
against human prolyl 4-hydroxylase beta (p4hβ, Millipore, 
Billerica, MA) and Alexa Fluor 568 goat anti-mouse 
secondary antibody (Invitrogen, Carlsbad, CA). GFP-hMSCs 
grown on coverslips served as antibody control. To identify 
rat monocytes and macrophages, a monoclonal antibody 
against CD68 (Millipore, Billerica, MA) was used and rat 
heart tissue without GFP-hMSCs injection served as 
antibody control. All tissue sections were counter-stained 
with 4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI, 
Invitrogen, Carlsbad, CA) to identify cell nuclei.  
 
Fig. (1). Tissue sections demonstrate GFP-hMSC distribution in 
LV. The LV was sectioned along a sagittal plane, parallel to the 
septum, in 10 µm sections spanning the epicardial (a) to 
endocardial (c) surface. Panels a- c illustrate representative sections 
through the LV, epicardium, mid-myocardium and endocardium, 
identifying GFP-hMSCs in each section.  
Imaging 
 Tissue sections were imaged on a Zeiss Axiovert inverted 
fluorescence microscope equipped with an Axiocam Mrc5 
camera (Carl Zeiss, Germany). Sequential fluorescence 
images of the sectioned LV were acquired with a 5x 
objective, identifying the GFP positive regions. For each 
animal, an average of 88 tissue sections were imaged, 
spanning an average depth of 1.5 mm. The GFP positive 
fluorescent images were converted to binary images using 
ImageJ software (http://rsb.info.nih.gov/ij/index.html). The 
binary images were used to calculate an average area of GFP 
positive cells. The Calvieri method [15] was used to estimate 
the GFP positive volume in each LV. For each image, the 
mean GFP positive area was calculated (µm2) and summed. 
The GFP positive volume, estimated as µm3, was calculated 
with equation 1 where the interval between tissue sections 
was 20µM. 
∑(Area of GFP positive cells)(Interval between tissue 
sections) = GFP positive volume  (1) 
 To estimate the average cell volume of the hMSC injec-
tion, confocal fluorescent images of hMSCs in suspension 
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were acquired. The average measured diameter of the spher-
ical cells was 10 µm, corresponding to an average cellular 
volume of 524 µm3 per cell. This cell volume approximation 
was used to estimate the percentage of hMSCs delivered to 
and retained in the LV where each injection consisted of 5 x 
105 cells/10 µl PBS. Equation 2 was used to estimate the 
hMSC injection and retention volume in GFP positive tissue 
sections. 
Estimated # of GFP-hMSCs = GFP positive volume (µm3)/ 
Average cell volume (µm3)  (2) 
 Immunofluorescent images of human p4hβ and rodent 
CD68 were acquired with a Zeiss Axiovert fluorescence 
microscope using a 10x objective. 
Statistics 
 The data is presented as mean ± SEM. The statistical 
significance was determined using an analysis of variance 
(ANOVA) and Tukey post hoc analysis where appropriate. 
A value of p<0.05 was considered statistically significant. 
RESULTS 
Animal Survival 
 A total of 25 animals received LV injections of GFP-
hMSCs. Seventeen animals survived and were analyzed for 
GFP-hMSC retention (4 were lost due to early death, and 4 
due to technical errors).  
Distribution of GFP-hMSC in LV 
 The estimated number of GFP-hMSCs retained at each 
injection site was determined from measurements acquired 
from the serial tissue sections as described in the Methods 
and shown in Fig. (1). The distribution of GFP-hMSCs in the 
LV was variable despite a consistent delivery technique. The 
variability of five GFP-hMSC injections measured in the LV 
at 30 minutes after delivery (Group A) is shown in Fig. (2). 
The average GFP positive areas ranged from 12,302 ± 
13,126 µm2 to 93,719 ± 84,197µm2 with GFP-hMSC distri-
bution in animals A-1, A-2 and A-3 distributed throughout 
the LV. However, GFP-hMSC delivery in animal A-4 was 
deeper in the LV and GFP-hMSC delivery in animal A-5 
 
Fig. (2). Variability of hMSC injections measured 30 minutes after delivery (Group A). Graph shows GFP-hMSC distribution in the LV from 
five hMSC injections (A-1 through A-5). The average GFP positive area ranged from 12,302 ± 13,126 µm2 to 93,719 ± 84,197 µm2. The 
GFP-hMSCs in A-1, A-2 and A-3 distributed throughout the LV, while the GFP-hMSCs of A-4 were delivered deeper in the LV and the 
GFP-hMSCs of A-5 were closer to the epicardium.  
 
 
Fig. (3). Three-dimensional reconstruction of GFP positive volume from Group B LV sections. The Z axis represents the epicardial to 
endocardial surface. Note the distribution of the GFP-hMSCs throughout the LV. 
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was closer to the epicardium. A representative image ren-
dered from the 10 µm fluorescent tissue sections illustrates a 
three-dimensional GFP-hMSC volume distribution at 24 
hours (Fig. 3).  
GFP-hMSC Retention 
 The average GFP positive volume calculated from the 
LV sections in Group A (30 minutes), Group B (24 hours), 
and Group C (5 days) are shown in Fig. (4). A significantly 
greater GFP positive volume was detected in Group A vs. 
Group C (8.2 x 107 ± 3.4- x 107 µm3 vs.1.6 x 106 ± 1.0 x 106 
µm3, p<0.05). These volumes correspond to an estimated cell 
retention of 31% or 1.6 x 105 ± 0.1 x 105 cells for Group A, 
9% or 4.4 x 104 ± 0.5 x 104 cells for Group B and 1% or 5.2 
x 103 ± 5.2 x 103 cells for Group C. The presence of human 
cells was evaluated with the co-localization of human p4hβ 
with GFP-hMSCs in the LV. Only LV tissue sections from 
Groups A and B stained positive for human p4hβ which co-
localized with the GFP-hMSCs. Representative images are 
shown in Fig. (5). In LV sections from Group C human p4hβ 
was not detected although negligible amounts of GFP 
fluorescence was detected. 
Immune Response 
 To ascertain the role of immune cells on hMSC engraft-
ment and retention LV tissue sections were probed for the 
 
Fig. (4). Average GFP positive volume (µm3) measured from imaged tissue sections (mean ± SEM ) corresponds to estimated percentage of 
hMSCs retained in cardiac tissue after transplantation. Thirty minutes post-injection, 31% of the GFP-hMSCs were detected in the LV. This 
contrasts with the 1% of GFP-hMSCs detected at 5 days post injection. A significant decrease in GFP-hMSC was detected in Group A vs. 
Group C (p<0.05).  
 
Fig. (5). Fluorescence images identifying hMSCs in rat LV tissue sections 30 minutes (Group A) and 24 hours (Group B) after hMSC 
transplantation. Panels (a) and (d) show GFP-hMSCs (green), panels (b) and (e) show human p4hß (red) with the merged image in panels (c) 
and (f) demonstrating co-localization of the GFP with the human antibody. Cell nuclei are identified with DAPI (blue). Scale bar = 200 µm.  
Early Cell Loss with Cardiomyoplasty The Open Tissue Engineering and Regenerative Medicine Journal, 2012, Volume 5     21 
presence of monocytes/macrophages using a rat CD68 
antibody. In Group C, rat monocytes/macrophages were 
detected at the site of injection and correlated with decreased 
retention of GFP-hMSCs over the 5 day interval. Moreover, 
rat monocytes/macrophages were detected at the injection 
site in Group C Control LV (saline only). Representative 
images are shown in Fig. (6). Minimal CD68 was detected in 
the LV of Group B and no CD68 was detected in Group A. 
Rat heart tissue without GFP-hMSCs injection served as 
antibody control. 
DISCUSSION 
 Delivery methods for cellular cardiomyoplasty vary 
greatly. Common techniques include intracoronary injection 
via catheterization [17-19], direct intramyocardial injection 
[20] or attachment of a pre-seeded bioscaffold to the heart 
[21]. Intramyocardial injections, although invasive, offer the 
most direct and concentrated delivery of cells to the cardiac 
region of interest. Several reports have shown short-term 
benefits of MSC injections administered in this manner [20, 
22, 23]. These transitory benefits, such as an increased 
ejection fraction in infarcted hearts, may be due to delivering 
cells that could potentially integrate into the host myocar-
dium, secrete soluble growth and angiogenic factors, or 
recruit the host’s own resident stem cells [1, 24, 25]. 
Although the exact mechanisms remain unknown, in order 
for cellular cardiomyoplasty to provide any long-term func-
tional benefits, delivered cells should ideally survive and be 
retained within the myocardium beyond a few days. As 
shown in this study, we demonstrate that only a small 
percentage of delivered hMSCs are found very early post 
delivery (30 minutes) to the myocardium despite being 
directly injected. In fact, the number of retained cells signi-
ficantly declines over the ensuing five days. The concomit-
ant loss of human p4hβ expression confirmed this finding. 
Furthermore, we have shown that within 5 days after intra-
myocardial injection, there exists a significant immune 
response creating a hostile environment for hMSCs. 
 Cell loss during intramyocardial injection can occur for a 
variety of reasons. The beating heart is the most mechanic-
cally active organ in the body. In a rat model, average heart 
rates can exceed 240 beats per minute. Obvious technical 
challenges associated with injecting into the beating myocar-
dium exist. Shallow injections may result in excessive 
washout whereas deeper injections may inadvertently deliver 
hMSCs into the left ventricle and circulatory system. Here, 
we have shown that approximately 31% of injected hMSCs 
were retained at the injection site in a beating rat heart model 
at 30 minutes after delivery. Teng and colleagues [12] 
documented massive loss (ranging from 90-98%) of 
microspheres (surrogates for cells) within 10 minutes after 
injection in beating normal rat model even with a purse-
string occlusion at the injection site. In a porcine model, our 
group has shown that approximately 10% of injected micro-
spheres were retained within the injection site. Interestingly, 
we also demonstrated that even with cardiac standstill using 
cardiopulmonary bypass, retention rates of microspheres 
were not significantly different [11]. This would suggest that 
loss of injected material was due to other factors besides 
mechanical loss at the injection site due to the contractile 
force of the myocardium. In fact, it would imply that there 
was an internal washout within the myocardial veins and 
 
Fig. (6). Immune response at 24 hrs and 5 days post hMSC transplantation. Fluorescent images of representative LV sections 24 hours 
(Group B), 5 days post hMSC injection (Group C) and 5 days post saline injection (Group C control). GFP-hMSCs (green), cell nuclei with 
DAPI (blue), immune response by the macrophage marker CD68 (red) and merged images are shown (overlay). Note the decrease in GFP 
fluorescence and increase in CD68 in the LV at 24 hours and 5 days post GFP-hMSCs injection versus control. At 24 hours post saline 
injection Group B control showed no difference in CD68 fluorescence (image not shown). Scale bar =200 µm.  
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lymphatics taking away the majority of injected material. 
When examined, microspheres were found in organs besides 
the heart. Presumably, similar factors are at work in our cur-
rent model described here, resulting in an acute loss of 
delivered hMSCs from the host myocardium. Others have 
documented similar results [26]. Hou and coworkers evalua-
ted the short term fate (one hour) of radiolabeled cells deli-
vered intramyocardially in a beating ischemic heart swine 
model [27] . They documented a retention rate ranging from 
8-14% within the heart and widespread distribution within 
the visceral organs. Furthermore, they also showed that an 
average of 12% of labeled cells were retained in the delivery 
device after injection. For this reason, in this study, we used 
a Hamilton syringe which by design has no dead space. 
 Besides the mechanical forces associated with acute 
hMSC loss during intramyocardial injection, other biological 
influences may contribute to the poor retention rate of 
hMSCs within the myocardium. Recently, attention has been 
drawn to the hypoxic environment that might be created by 
the injection itself [28, 29]. A significant amount of hMSCs 
are delivered to a small area and that volume significantly 
decreases local perfusion as evidenced by the blanching of 
myocardial tissue witnessed with each injection. Even within 
non-ischemic hearts, this may create conditions that are 
unfavorable for acute cell survival resulting in death of the 
injected hMSCs. Logically, one could then assume that 
smaller injectate volumes delivered to multiple areas might 
yield a higher cumulative retention and survival rate than one 
large injectate volume. Ott and colleagues have described 
this observation in a rat infarct model [30]. Intramyocardial 
cell delivery performed with smaller, more numerous, 
injections resulted in improved cardiac function and a larger 
number of engrafted cells. The authors speculated that these 
findings may have resulted from an increased surface to 
volume ratio in each injection allowing increased contact 
area between injected cells and host myocardium. Further 
investigations to confirm these observations seem warranted 
in light of poor retention rates observed in our study. 
 To locate the transplanted GFP-hMSCs we sectioned the 
LV in 10 µm sections along the sagittal plane from the 
epicardial surface towards the endocardium. This allowed us 
to image the tissue at 20 um intervals, carefully documenting 
the hMSC distribution in each LV. This analysis clearly 
demonstrated the variability in delivered hMSC distribution 
among animals and the importance of careful sampling. 
Unlike many histological studies that report hMSC retention 
from random tissue sections, we analyzed hMSC distribution 
in the entire LV. The Calvieri method [15, 31-33] provided a 
quantitative measure of the irregular GFP-hMSC volume 
distribution in the LV. Using this method to estimate GFP 
positive volume in the LV and correlating this volume to the 
percent retained GFP-hMSCs revealed that over 50% of the 
hMSCs were lost within the first 30 minutes after delivery. 
These estimates agree with similar measurements of stem 
cell retention using positron emission tomography to locate 
cardiac-derived stem cells in beating rat heart infarct model 
[34]. 
 Aside from the above mentioned influences that contri-
bute to acute cell loss, there are other biological factors that 
contribute to chronic cell loss. Our data demonstrate that 
there is a continual decrease in the retention of injected 
hMSCs and by 5 days injected hMSCs are virtually impossi-
ble to identify using GFP. The lack of staining for human 
p4hβ in the myocardial tissue confirmed this observation. 
Concurrent loss of GFP and p4hβ at 5 days suggests the 
transplanted hMSCs are not present, having either died or 
migrated elsewhere, they haven’t simply just lost their ability 
to fluoresce. Mechanical loss and cell death can certainly 
continue to contribute to the significant decline during this 
time. However, other more chronic processes such as the 
host’s own immune system must play a significant role in 
hMSC loss as well. Therefore, using a rat CD68 antibody to 
identify monocytes and macrophages, we were able to 
demonstrate that there is a considerable increase in mono-
cytes and macrophages at the injection site. Presumably, the 
remaining hMSCs are further challenged by a localized 
cellular inflammatory response within the injection area. In 
contrast, there was very little evidence of an immune res-
ponse 30 minutes after intramyocardial injection as demons-
trated by the lack of staining for rat CD68 in Group A. Even 
more interesting, was the fact that we observed a significant 
and similar immune response at 5 days within the control 
group (saline injection only). This would suggest that the 
injection itself creates an injury within the myocardium that 
causes a host immune response. This finding highlights a 
potentially significant limitation of the intramyocardial injec-
tion as a delivery method for cell cardiomyoplasty. Further 
substantiating the host cellular response to the injection is 
our DAPI staining (nuclear counterstain) at 5 days post 
injection that showed a large number of cells within the 
injection site which were not present at 30 minutes or 24 
hours after injection. Ultimately, the micro-environment that 
may be created by myocardial injections may not be suitable 
for continued survival of transplanted cells.  
 The use of a xenograft model of human MSCs delivered 
into rat myocardium has several limitations. We chose this 
model to maximize our ability to differentiate between host 
and transplanted cells using species specific markers.While 
we used GFP to label cells, other methods such as antibodies 
to human mitochondria could have been used as well [35]. 
Concern may be raised about the xenogenic immune res-
ponse that could be elicited from these injections. However, 
hMSCs lack MHC Class II antigens and co-stimulatory 
molecules and have previously been shown to not induce 
xenoreactivity in immunocompetent Sprague-Dawley rats 
[36], although significant controversy still exits. Neverthe-
less, hMSCs may evade immunosurveillance [37]. For exam-
ple, allogeneic MSCs injected into infarcted myocardium in 
a pig model showed no signs of rejection and reduced infarct 
size via myocardium regeneration [24]. Therefore, we elec-
ted not to immunosuppress recipient animals. However, 
future studies with athymic rats could further help disting-
uish immunological vs. non-immunological mechanisms of 
cell loss. Furthermore, we did not examine peripheral organs 
for washout of injected cells. Based on prior results, we 
would anticipate substantial numbers of hMSCs in the lungs, 
liver and spleen [11].  
CONCLUSION 
 We show that there is significant loss of hMSCs after 
intramyocardial delivery that begins almost immediately 
after the injection is complete. This loss continues for up to 5 
Early Cell Loss with Cardiomyoplasty The Open Tissue Engineering and Regenerative Medicine Journal, 2012, Volume 5     23 
days at which point almost all transplanted hMSCs have 
either been washed out of the myocardium or died as a result 
of a significant host cellular immune response. Future 
experiments might try to alter the delivery method. Smaller, 
more numerous injections may yield a higher total cell 
retention count than a single large injection, especially in a 
small heart such as the rat. Modulating the immune response 
locally might also improve chances of long term engraft-
ment. Nevertheless, our data supports concerns that the 
optimal delivery method has not been established. Continued 
work in this area is imperative if cellular cardiomyoplasty is 
to have any meaningful long-term clinical impact. 
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